The stock of Merck & Co Inc (NYSE:MRK) last traded at $122.20, up 0.63% from the previous session.
MRK stock price is now -0.90% away from the 50-day moving average and 10.18% away from the 200-day moving average. The market capitalization of the company currently stands at $309.49B.
With the price target maintained at $104, Societe Generale recently Downgraded its rating from Hold to Sell for Merck & Co Inc (NYSE: MRK). On January 04, 2024, TD Cowen Upgraded its previous ‘Market Perform’ rating to ‘Outperform’ on the stock increasing its target price from $125 to quote $135, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Merck & Co., Inc., 10% Owner bought 21,397,205 shares of the company’s stock on Mar 11 ’24. The stock was bought for $492,135,715 at an average price of $23.00. Upon completion of the transaction, the 10% Owner now directly owns 1,000 shares in the company, valued at $0.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 14 ’24, Chairman, CEO & President Davis Robert M sold 85,021 shares of the business’s stock. A total of $10,661,574 was realized by selling the stock at an average price of $125.40. This leaves the insider owning 348,327 shares of the company worth $42.57 million. A total of 0.15% of the company’s stock is owned by insiders.
During the past 12 months, Merck & Co Inc has had a low of $99.14 and a high of $130.24. As of last week, the company has a debt-to-equity ratio of 0.97, a current ratio of 1.25, and a quick ratio of 1.00. According to the stock market information, the enterprise value for the company is $335.53B, which is based on a 924.36 price-to-earnings ratio, a 13.71 price-to-earnings-growth ratio, and a beta of 0.39. The fifty day moving average price for MRK is $123.31 and a two-hundred day moving average price translates $110.91 for the stock.
The latest earnings results from Merck & Co Inc (NYSE: MRK) was released for Dec, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.03, beating analysts’ expectations of -$0.11 by 0.14. This compares to $1.18 EPS in the same period last year. The net profit margin was 0.61% and return on equity was 0.87% for MRK. The company reported revenue of $14.63 billion for the quarter, compared to $13.83 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.79 percent. For the current quarter, analysts expect MRK to generate $15.12B in revenue.
Merck & Co Inc(MRK) Company Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
